NCT04531046
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04531046
Title Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors The Lymphoma Academic Research Organisation
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA | BEL

Facility Status City State Zip Country Details
CH Liège Liège 4000 Belgium Details
CHU de Bordeaux - Hôpital Haut Lévêque Bordeaux France Details
CHU Clermont Ferrand - Hôpital Estaing Clermont-Ferrand France Details
APHP - Hôpital Henri Mondor Créteil France Details
CHU de Dijon - Hôpital le Bocage Dijon 21000 France Details
Hôpital Claude Huriez Lille 59037 France Details
Hôpital Saint Eloi Montpellier 34295 France Details
CHU de Nantes - Hôtel Dieu Nantes 44093 France Details
APHP - Hôpital Saint Louis Paris 75475 France Details
Hopital La Pitié Salpétriere Paris France Details
Hôpital Saint Antoine Paris France Details
Centre Hospitalier Lyon Sud Pierre-Bénite 69495 France Details
CHU de Rennes - Hôpital de Pontchaillou Rennes 35003 France Details
IUCT Oncopole Toulouse France Details
CHU Brabois Vandœuvre-lès-Nancy 54511 France Details
Institut de Cancérologie Gustave Roussy Villejuif France Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field